NewAmsterdam Pharma Company N.V. Warrant - NAMSW STOCK NEWS

Welcome to our dedicated page for NewAmsterdam Pharma Company N.V. Warrant news (Ticker: namsw), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V. Warrant stock.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases. Their product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to overcome the limitations of current LDL-C lowering treatments. The company is focused on developing innovative therapies for cardiovascular diseases where existing treatments are inadequate or not well-tolerated.

The latest updates from the company include financial results for the fourth quarter and full year of 2023, corporate developments, and ongoing clinical trials of obicetrapib. With significant progress in clinical execution, NewAmsterdam aims to revolutionize patient outcomes and deliver value to its shareholders.

2023 was marked by positive clinical data from various Phase 2 trials, demonstrating significant LDL-lowering and a favorable safety profile. The company is currently conducting pivotal Phase 3 trials, including BROOKLYN, BROADWAY, PREVAIL, and TANDEM, to evaluate the efficacy and safety of obicetrapib in different patient populations.

09/20/2023 08:00 AM

News

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

Rhea-AI Summary

NewAmsterdam Pharma CEO to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.1%

Tags

08/14/2023 04:01 PM

News

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

Rhea-AI Summary

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) appoints William "BJ" Jones as Chief Commercial Officer, signaling the company's strategic move to build a powerful commercial organization and prepare for the potential launch of obicetrapib, a promising oral therapy for patients at high risk of cardiovascular disease.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.8%

Tags

08/07/2023 07:15 AM

News

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

Rhea-AI Summary

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced positive clinical trial results for obicetrapib and ezetimibe, met primary endpoints with significant LDL-C reductions, and completed a secondary offering. The company's focus on pivotal Phase 3 trials and upcoming milestones indicates strong growth potential.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.28%

Tags

07/25/2023 04:01 PM

News

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

Rhea-AI Summary

NewAmsterdam Pharma Company N.V. has completed patient enrollment in the Phase 3 BROADWAY clinical trial for obicetrapib, a non-statin medicine for patients at high risk of cardiovascular disease. The target enrollment of 2,400 subjects was exceeded, with over 2,500 patients expected to be randomized. Topline results are expected in the second half of 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.72%

Tags

06/09/2023 04:01 PM

News

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

Rhea-AI Summary

NewAmsterdam Pharma Company N.V. has closed its underwritten public offering of 15,787,695 ordinary shares. The offering price was $11.50 per share, with no proceeds going to the company. Jefferies and SVB Securities acted as joint book-running managers for the offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.77%

Tags

06/06/2023 11:25 PM

News

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-16.52%

Tags

06/06/2023 04:01 PM

News

NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-16.52%

Tags

06/05/2023 07:00 AM

News

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.54%

Tags

06/03/2023 12:15 PM

News

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/31/2023 08:00 AM

News

NewAmsterdam Pharma to Present at Jefferies Healthcare Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.07%

Tags

FAQ

What is the current stock price of NewAmsterdam Pharma Company N.V. Warrant (namsw)?

The current stock price of NewAmsterdam Pharma Company N.V. Warrant (namsw) is $6.97 as of September 4, 2024.

What is NewAmsterdam Pharma known for?

NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on improving patient care in metabolic diseases, particularly cardiovascular.

What is obicetrapib and its significance?

Obicetrapib is a next-generation CETP inhibitor developed by NewAmsterdam to overcome the limitations of current LDL-C lowering treatments, offering potential benefits for patients at risk of cardiovascular diseases.

What are the company's key achievements in 2023?

In 2023, NewAmsterdam reported significant progress in clinical execution, positive data from Phase 2 trials, and expansion of their team, emphasizing commitment to revolutionizing patient outcomes and delivering value to shareholders.

What are the upcoming milestones for NewAmsterdam?

NewAmsterdam expects to achieve milestones like topline results from BROOKLYN and BROADWAY, initiation of the TANDEM trial, completion of PREVAIL enrollment, and strategic investments in the commercial organization.

How does obicetrapib differ from existing therapies?

Obicetrapib aims to be a once-daily oral CETP inhibitor with strong tolerability and LDL-lowering effects, potentially offering an improved treatment option for patients with cardiovascular risks.

What is the focus of NewAmsterdam's clinical development strategy?

NewAmsterdam's clinical development strategy revolves around multiple pivotal Phase 3 trials evaluating obicetrapib's efficacy and safety in different patient populations at risk of cardiovascular diseases.